AxoSim's Nerve-on-a-Chip™ platform facilitates prediction of both clinical neurotoxicity and efficacy in human neurodegenerative disease models earlier in the drug development pipeline.


Up-and-Coming AxoSim Hiring Scientists After Landing Research Grants to Speed Research

AxoSim, a biotech company headquartered in New Orleans, recently received two government grants totaling $455,000.

Read Full Article